Publication | Closed Access

Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma

Lymphoid NeoplasiaMedicineMalignant Blood DisorderImmunologyYttrium 90–LabeledDurable RemissionsImmunotherapyOncologyRadiation Oncology